Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
49.28
+0.59 (+1.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
24
25
Next >
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
April 18, 2023
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.
Via
Benzinga
AbbVie Stock Shows Improved Relative Price Strength
April 13, 2023
AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see.
Via
Investor's Business Daily
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
April 12, 2023
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...
Via
Benzinga
Is Sanofi Stock a Buy Now?
March 25, 2023
The pharma giant has outperformed the broader market over the past 12 months.
Via
The Motley Fool
Looking Into Sanofi's Recent Short Interest
March 23, 2023
Via
Benzinga
Why Shares of Regeneron Are Rising Thursday
March 23, 2023
Regeneron released positive phase 3 trial results for its therapy Dupixent.
Via
The Motley Fool
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information
April 11, 2023
Via
Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...
Via
Benzinga
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens
April 10, 2023
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday
Via
Investor's Business Daily
2 Top Healthcare Stocks Defying the Bear Market
April 07, 2023
The market sell-off over the past year hasn't stopped these healthcare giants from rallying.
Via
The Motley Fool
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
April 06, 2023
Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years.
Via
The Motley Fool
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
March 23, 2023
The companies' Dupixent reduced exacerbations by 30%.
Via
Investor's Business Daily
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
March 17, 2023
Via
Benzinga
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
March 30, 2023
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease.
Via
The Motley Fool
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
March 27, 2023
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.
Via
Investor's Business Daily
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
March 25, 2023
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication.
Via
The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
March 24, 2023
The major indexes showed volatile, divergent action.
Via
Investor's Business Daily
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
March 24, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met...
Via
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
March 24, 2023
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial...
Via
Benzinga
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
March 23, 2023
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent.
Via
InvestorPlace
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
March 23, 2023
Bloomberg
Via
Benzinga
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
March 23, 2023
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial.
Via
Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
March 20, 2023
Reuters
Via
Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
March 20, 2023
Via
Benzinga
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
March 17, 2023
A market rally is underway, but bank stocks kept tumbling.
Via
Investor's Business Daily
SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories
March 17, 2023
Benzinga
Via
Benzinga
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
March 17, 2023
Via
Benzinga
Why Provention Bio Stock Skyrocketed 256% This Week
March 16, 2023
Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker.
Via
The Motley Fool
What's Going On With Sanofi Stock After Hours?
March 16, 2023
Sanofi SA (NASDAQ: SNY) is buzzing in Thursday's after-hours session after the company said it will cut the list price of its most widely prescribed insulin in the United States
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
24
25
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.